Evidence map›Paper›PMID 36646089›Full record

ReviewSeminars in respiratory and critical care medicine2023

Glucocorticoid Therapy in COVID-19.

Francesco Amati, Antonio Tonutti, John Huston, Charles S Dela Cruz

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Journal of inflammation research · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Francesco AmatiRespiratory Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Antonio TonuttiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
John HustonSection of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Critical Care and Sleep Medicine, Center for Pulmonary Infection Research and Treatment, Yale School of Medicine, New Haven, Connecticut.
Charles S Dela CruzSection of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Critical Care and Sleep Medicine, Center for Pulmonary Infection Research and Treatment, Yale School of Medicine, New Haven, Connecticut.
Humanitas University · ITYale University · US

Funding

Training Translational Lung Biology and PathobiologyT32HL007778 · NHLBI · YALE UNIVERSITY · PI Erica L Herzog, NAFTALI KAMINSKI · 1994 to 2026
$14.4M
NHLBI NIH HHS T32 HL007778
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality in pandemic proportions. Inflammation in response to the infection contributes to the pathogenesis of pneumonia. This review will discuss prior studies on the use of glucocorticoids to treat respiratory infections, the rationale for the use glucocorticoids in COVID-19, and review of existing data. We will also highlight outstanding research questions for future studies.

Indexed as

COVID-19GlucocorticoidsHumansInflammationSARS-CoV-2Glucocorticoids

Identifiers

PMID36646089
PMCPMC10963066
OpenAlexW4316591199

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.